Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin for neonatal perinatal arterial ischemic stroke
NL-OMON58613Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of darbepoetin alfa, sponsored by University Medical Center Utrecht. Started Aug 2024; status: recruiting.
02
Drugs
darbepoetin alfa
Beyond the preview
Go deeper on NL-OMON58613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58613.